Notable profits for the buyer who lifted the $0.30 offer for 4,269 TG Therapeutics (TGTX) Feb-23 20 calls yesterday at 13:52ET when underlying shares were trading at $17.85. Shares closed at $17.90, and the calls at $0.57 for a mark-to-market profit of 91%, or $117K, on the $128K outlay.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TGTX:
- TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
- TG Therapeutics management to meet virtually with Cantor Fitzgerald
- TG Therapeutics announces commercial launch of BRIUMVI
- TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
- TG Therapeutics price target raised to $25 from $16 at Evercore ISI